RWM
MIST icon

Rialto Wealth Management’s Milestone Pharmaceuticals MIST Stock Holding History

Rialto Wealth Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$402 Hold
300
– – ﹤0.01% 1778
2026
Q1 		$357 Hold
300
– – ﹤0.01% 1503
2025
Q4 		$606 Buy
+300
New +$646 ﹤0.01% 1181

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Rialto Wealth Management's MIST Position: Q2 2026 in Review

Rialto Wealth Management held its Milestone Pharmaceuticals (MIST) position steady in Q2 2026 at 300 shares worth $402. The position accounts for ﹤0.01% of the portfolio, ranked #1778.

Rialto Wealth Management first reported a position in MIST in Q4 2025 and has held it in 3 quarters since. The position peaked at $606 in Q4 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Rialto Wealth Management held 300 shares of Milestone Pharmaceuticals worth $402 as of Q2 2026.
  • Rialto Wealth Management left its Milestone Pharmaceuticals share count unchanged in Q2 2026.
  • Milestone Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1778 holding.
  • Rialto Wealth Management first reported a position in Milestone Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Rialto Wealth Management's Milestone Pharmaceuticals position peaked at $606 in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.